Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AB-1003 in LGMD2I/R9
NCT05230459Phase 2Active, not recruiting
- Sponsor
- AskBio
- Start
- May 2023
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 2 trial of AAV gene therapy for LGMD 2I/R9 in limb-girdle muscular dystrophy type 2I (LGMD2I), sponsored by AskBio. Started May 2023; status: active, not recruiting.
02
Drugs
AAV gene therapy for LGMD 2I/R9
03
Conditions
limb-girdle muscular dystrophy type 2I (LGMD2I)
Beyond the preview
Go deeper on NCT05230459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05230459.